 Elancos worldwide business, pharmaceuticals, and food additives for pets and farm animals is recession-resistant - and growing rapidly. Since the 20182019 spin-off from Eli Lilly, Elanco has struggled to gain its operational and financial footing more than the comparable Zoetis. 